Small molecules capable of dusripting WD-repeat domain interactions with key binding partners have been developed for other proteins, suggesting that the RFWD3-RPA32 interaction could be a tractable target to sensitize cancers to cisplatin93. The gene discussed is RFWD3; the disease is cancer.